TARS — Tarsus Pharmaceuticals, Inc.

Tarsus Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Product Sales: $151.7 million, with a gross-to-net discount of 44%.
• Full Year 2025 Net Sales: $451.4 million, gross-to-net discount approximately 45%.
• Operating Expenses: $522.3 million, primarily due to commercial investments for XDEMVY.
• Cash Position: Approximately $418 million in cash, cash equivalents, and marketable securities.
• 2026 Revenue Guidance: Expected net product sales between $670 million and $700 million, reflecting over 50% growth at the midpoint.

2. Strategic Updates and Business Highlights

• XDEMVY Performance: The product is now profitable and has helped over 0.5 million patients, with a potential market of 25 million Americans suffering from Demodex blepharitis.
• Future Sales Potential: Management anticipates XDEMVY could achieve blockbuster status with sales exceeding $2 billion.
• Pipeline Expansion: Tarsus is advancing clinical programs TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, with Phase II trials expected to start in 2026.
• Sales Force Expansion: Plans to add 15-20 key account leaders to deepen engagement with high-opportunity practices.
• Direct-to-Consumer (DTC) Campaign: The campaign has shown a positive return on investment, with plans to maintain a similar spending level in 2026.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated strong growth in net sales, with a seasonal impact expected in Q1 due to deductible resets and other factors.
• Operating Expenses for 2026: SG&A expenses projected between $545 million and $565 million, with R&D expenses between $115 million and $135 million.
• Long-term Profitability: Management aims for increasing operating leverage as revenue scales, with a clear path toward potential profitability.

4. Challenges and Points of Concern

• Q1 Revenue Expectations: Anticipated to be flat to slightly below Q4 2025 due to seasonal dynamics affecting new patient visits and increased out-of-pocket costs.
• Gross-to-Net Discount Pressure: Expected to remain elevated in Q1 before stabilizing in the 43%-45% range later in the year.
• Market Dynamics: Continued reliance on new patient prescriptions may expose Tarsus to fluctuations from seasonal events and market disruptions.

5. Notable Q&A Insights

• Prescribing Trends: Both optometrists and ophthalmologists are increasing their prescribing rates, with 40% of the core target prescribing weekly.
• Peak Sales Guidance: The $2 billion peak sales target is specific to the U.S. market, with expectations for significant growth driven by expanding prescriber engagement and patient awareness.
• DTC Campaign Effectiveness: The campaign has significantly raised patient awareness from 2% to 25%, enhancing the likelihood of patient conversions.
• Clinical Trial Costs: The ocular rosacea trial is expected to cost $7 million to $10 million, while the Lyme disease trial is projected to cost $25 million to $30 million.

Overall, Tarsus demonstrated strong financial performance in 2025, with ambitious growth plans and a robust pipeline, although it faces challenges related to seasonal revenue fluctuations and gross-to-net pressures.